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Purpose: To evaluate the probable toxic effects of amiodarone on 
retina, using electrooculography (EOG) and electroretinography 
(ERG) testing methods.
Patients and Methods: Fifty participants in the present study 
included 25 patients with a history of amiodarone treatment as 
the case group and 25 age, sex and visual acuity matched healthy 
volunteers with healthy visual system as the control group.  All the 
participants underwent EOG and ERG examinations on their both 
eyes. The results obtained in two groups were compared to look 
for possible changes among patients undergoing treatment with 
amiodarone compared to the control group.
Results: There was no statistically significant difference between 
the case and control groups regarding the age, sex, and visual 
acuity. Out of 50 eyes in the case group 9 eyes showed abnormal 
ERG including 7 eyes showing abnormal b-wave peak latency 
and 5 eyes showing abnormal b-wave peak amplitude. Three 
eyes had both abnormal latency and amplitude. In comparison, 
only one eye in the control group showed abnormal latency. The 
difference between the two groups in number of participants 
showing abnormal b-wave peak latency (P = 0.022) or amplitude 
(P =  0.027) were both statistically significant. Regarding the EOG 
testing 15 eyes among patients and 10  eyes from controls showed 
abnormal EOG Arden index indicating no statistically significant 
difference (P =  0.248).
Conclusion: Based on the results of the present study we can 
conclude that amiodarone has toxic effects on retina, which might 
be detected and followed using ERG b-wave latency and amplitude.
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Introduction
Amiodarone is used to treat and prevent a 
number of heart beat arrhythmias, congestive 
heart failure, and also in patients after 
acute myocardial infarction 1. Ventricular 
tachycardia, ventricular fibrillation, wide 
complex tachycardia and atrial fibrillation are 
among the most common arrhythmias that can 
be treated using amiodarone 2. 
Amiodarone may cause hepatotoxicity and 
symptomatic hepatic dysfunction, cirrhosis, 
peripheral neurotoxicity, nausea, vomiting 
and muscle weakness 3. Amiodarone also has 
certain side effects on visual system mainly 
affecting the anterior segment including 
cornea and lens, as well as optic nerve and 
retinal side effects 4. These side effects might 
cause visual loss, swelling of the optic disc 
and abnormal blue color vision 4,5. After 
discontinuation of amiodarone either a visual 
stabilization, improvement, or a permanent 
deterioration may result 6-8. 
As mentioned before retina and visual 
pathways may be affected by amiodarone. 
Shushtarian et al., 9 have reported a 39 year old 
patient with a history of amiodarone usage and 
chief complaint of seeing colored rings around 
the lights. The patient underwent different 
electrophysiological eye examinations such as 
visual evoked potential (VEP), ERG and EOG, 
which all showed abnormal results 9. After 
the discontinuation of the drug the patient 
complains were subsided 9. 
There are few previous studies reporting the 
effect of amiodarone retinal toxicity in ERG 
and EOG exams 10. The aim of the present 
study was to further investigate the ERG and 
EOG findings among patients with a history of 
amiodarone usage.  
Patients and Methods
Twenty five patients with a history of 
amiodarone usage with a dosage of at least 
400 mg daily in the last six months entered 
the present study as the case group. The 
patients were selected from a large population 
of patients with a history of amiodarone 
prescription. The control group included 25 
age, sex and visual acuity matched volunteers 
with healthy visual system and no history of 
amiodarone usage. The present study was 
approved by the ethics committee of Basir 
Eye Health Research Center, Tehran, Iran, and 
all participants gave written consent before 
entering the study. 
All participants underwent electrooculography 
(EOG) and electroretinography (ERG) testing.
Biomedical Mangoni instrument, 
which is capable of recording different 
electrophysiological tests, was used for testing 
the ERG and EOG in all participants. To 
perform EOG testing the patient’s eye was pre-
dark adapted for 15 minutes and the subject 
was asked to rotate his eyes simultaneously 
between the three bulbs fixed in front of his 
eyes for 10 minutes and the corresponding 
potential changes were measured. The mean 
of these readings was considered as the light 
adaptation potential (LAP). Then the subject 
was dark-adapted for 10 minutes. The same 
procedure was followed for measuring the 
dark adaptation potential (DAP). The ratio of 
LAP to DAP potential which is called Arden 
index (AI) was calculated for all participants.
For ERG examination three electrodes were 
used to connect the subjects to the machine. 
Active, reference and earth electrodes were 
attached to cornea, earlobe and forehead 
respectively. The active electrode was a hard 
contact lens. A thread shape cotton, soaked 
with saline, was placed on the lens to extract 
the electrical response of retina and transfer 
it to the electrode. For two other electrodes 
electrophysiological conductive paste was 
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used between electrodes and skin. Before 
placing the contact lens the patient’s eyes 
were dilated with standard dilating eye 
drops. Also anesthetic drops were used to 
induce numbness of the eye. After placing the 
electrodes, the patient’s eyes were stimulated 
using a standardized flash of light. The signal 
produced is an ERG wave consisting of two 
waves (a wave and b wave). In the present 
study the latency (msec) and amplitude (μv) 
of ERG b-wave peak were measured for each 
participant. 
Results
Fifty eyes of twenty five patients, (17 males 
and 8 females) were examined as the case 
group. The same number of normal population 
entered the study as the control group.  The 
mean age of patients and the controls were 
44.96 ± 3.03 years and 45.24 ± 2.55 years, 
respectively, indicating no statistically 
significant difference (Table 1). 
Out of 50 eyes in the case group 9 eyes showed 
abnormal ERG including 7 eyes showing 
abnormal latency and 5 eyes showing abnormal 
amplitude. Three ayes had both abnormal 
latency and amplitude. In comparison, only 
one eye in the control group showed abnormal 
latency (Table 2). The difference between the 
two groups in number of participants showing 
abnormal b-wave peak latency (P = 0.022) or 
amplitude (P =  0.027) were both statistically 
significant. Regarding the EOG testing 15 eyes 
among patients and 10  eyes from controls 
showed abnormal Arden index indicating no 
statistically significant difference (P = 248) 
(Table 3).
Discussion
In the present study the patients in the case 
group showed significantly higher abnormal 
results in ERG b-wave peak amplitude and 
latency compared to the control group. There 
was no statistically significant difference 
between the case and the control group 
regarding the EOG Arden index.  Schmidt 
et al., 5 examined six patients with the mean 
age of 71.7 years (five male, one female) who 
Table 1: Demographic findings of study 
participants
Variable Group P value
Control Case
Age 45.24  ± 2.55 44.96 ± 3.03 0.726 *
Sex Male : 17 
Female: 8





Table 2: Compression of  results regarding the amplitude and latency of b-wave peak 




Normal Abnormal Normal Abnormal
Latency (msec) 49 1 43 7 0.022
Amplitude (µv) 50 0 45 5 0.027
Chi-Square Tests
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were treated with amiodarone. They found that 
one patient developed abnormal blue color 
vision, five patients showed swelling of the 
optic disc, which completely disappeared after 
discontinuing the drug, one patient showed 
posterior ischemic optic neuropathy (PION), 
two patients showed a unilateral change of 
the optic disc, and finally three patients had 
a severe irreversible lesion of the optic nerve 
at follow-up examination 3. Domingues et al., 
11 studied 14 patients undergoing long term 
amiodarone therapy using pattern reversal 
visual evoked potential and found a significant 
prolongation in latency and reduction in 
amplitude of VEP, P100 peak in comparison 
with the same parameters in normal population. 
Shaikh et al.,12 studied electrophysiological 
changes in patients undergoing amiodarone 
treatment using multifocal and full-field ERG. 
Their patients had received amiodarone at 
various dosages ranging from 100mg to 800mg 
daily for at least 15 months 12. In contrast to 
our findings in their study multifocal and full-
field ERG were mostly unremarkable, and 
the mildly subnormal findings in few patients 
showed no consistent pattern to suggest a toxic 
cause due to drug usage.
Conclusion
Based on the results of the present study we can 
conclude that amiodarone has toxic effects on 
retina, which might be detected and followed 
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Table 3: Compression of results regarding the ERG Arden index in the case and control 
groups
Descriptive Total Normal Abnormal P value *
group control 50 40 10 0.248
case 50 35 15
*Chi-Square Tests
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